Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC

Inclusion Criteria: * Signed written informed consent. * Age ≥18 years. * Newly diagnosed, unresectable, locally advanced (ineligible for curative concurrent - chemoradiotherapy) or metastatic NSCLC per AJCC 9th edition. * KRAS G12C mutation confirmed by validated testing. * PD-L1 TPS ≥1%. * ≥1 measurable lesion per RECIST v1.1. * No prior systemic therapy for advanced/metastatic NSCLC; prior adjuvant therapy allowed if completed \>6 months before dosing and toxicities recovered to ≤Grade 1. * ECOG PS 0-2. * Life expectancy \>3 months * Adequate organ function (hematologic, hepatic, renal, coagulation per protocol thresholds) * Negative pregnancy test for women of childbearing potential; adequate contraception for men and women through 3 months post-treatment * Willing and able to comply with study procedures and follow-up. Exclusion Criteria: * History of other malignancies (exceptions: cured basal cell carcinoma, cervical carcinoma in situ) * Predominant squamous NSCLC, small cell carcinoma, or neuroendocrine carcinoma. * Other actionable drivers (EGFR, ALK, ROS1, RET, BRAF, NTRK, MET, etc.). * Known hypersensitivity to study drugs. * Prior PD-1/PD-L1 inhibitors or KRAS inhibitors. * Active autoimmune disease or autoimmune disease history requiring systemic therapy. * Systemic immunosuppressive therapy within 14 days prior to first dose. * Symptomatic ascites/pleural effusion needing recurrent drainage. * Significant cardiovascular disease (NYHA ≥2, MI within 1 year, unc…